| Identification | Back Directory | [Name]
ACT-462206 | [CAS]
1361321-96-1 | [Synonyms]
ACT-462206
ACT-462206 >=98% (HPLC)
(2S)-N-(3,5-DIMETHYLPHENYL)-1-(4-METHOXYPHENYL)SULFONYLPYRROLIDINE-2-CARBOXAMIDE
(2S)-N-(3,5-Dimethylphenyl)-1-[(4-methoxyphenyl)sulfonyl]-2-pyrrolidinecarboxamide | [Molecular Formula]
C20H24N2O4S | [MDL Number]
MFCD28502270 | [MOL File]
1361321-96-1.mol | [Molecular Weight]
388.48 |
| Chemical Properties | Back Directory | [density ]
1.285±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
14.27±0.70(Predicted) | [color ]
White to off-white | [InChI]
1S/C20H24N2O4S/c1-14-11-15(2)13-16(12-14)21-20(23)19-5-4-10-22(19)27(24,25)18-8-6-17(26-3)7-9-18/h6-9,11-13,19H,4-5,10H2,1-3H3,(H,21,23)/t19-/m0/s1 | [InChIKey]
NHPQGZOBHSVTAQ-IBGZPJMESA-N | [SMILES]
O=S(N1CCC[C@H]1C(NC2=CC(C)=CC(C)=C2)=O)(C3=CC=C(OC)C=C3)=O |
| Hazard Information | Back Directory | [Uses]
ACT-462206 is a potent and selective dual orexin receptor antagonist (DORA) that inhibits the stimulating effects of the orexin peptides at both the orexin 1 and 2 receptors. It decreases wakefulness and increases non-rapid eye movement (non-REM) and REM sleep while maintaining natural sleep architectures in some animal models while showing anxiolytic-like properties without affecting cognition and motor function in others. | [Biological Activity]
ACT-462206 is a orally activebrain penetrantpotent and selective dual orexin1/2 receptor antagonist (DORA). ACT-462206 decreases wakefulnessdecreases sleep latencyand increases sleep efficacy in rats and dogs.''ACT-462206 is a proline sulphonamide with the potential to tre at insomnia. On absorptionits displays astheniablurred visionand fatigue as adverse events. | [in vivo]
ACT-462206 (compound 24) (100 mg/kg; p.o.; sampling at 3 h) can go cross blood brain barrier, with concentrations are 2267 ng/mL and 1219 ng/g in plasma and brain, respectively in male Wistar rats[1].
ACT-462206 (10-300 mg/kg; p.o.; single dose) shows sleep-promoting effects in male Wistar rats and in male Beagle dogs, with decreasing wakefulness and increasing non-rapid eye movement (non-REM) and REM sleep[1].
ACT-462206 (100, 300 mg/kg; p.o.; single dose) exerts anxiolytic-like effects, decreases the fear-potentiated startle reflexes in response to a sudden loud noise in rats, reduces the socialstress-induced increases of locomotion, body temperature, and heart rate[1].
Pharmacokinetics in different species[1]
| Route | Dose (mg/kg) | AUC (ng h/mL) | CL (mL/min/kg) | Vss (L/kg) | t1/2 (h) | cmax (ng/mL) | tmax (h) | F1/2 (%) | | rat | i.v. | 1 | 586 | 29 | 1.8 | 1.9 | / | / | / | | p.o. | 10 | 2310 | / | / | / | 1600 | 0.5 | 39 | | dog | i.v. | 1 | 1490 | 11 | 1.4 | 1.7 | / | / | / | | p.o. | 3 | 2750 | / | / | / | 426 | 0.5 | 52 |
| Animal Model: | Male Wistar rats[1] | | Dosage: | 0, 10, 30, 100, 300 mg/kg | | Administration: | Oral gavage; single dose | | Result: | Decreased the latency to the first persistent episode of non-REM sleep (60 s) and the first persistent episode of REM sleep (30 s).
Dose-dependently decreased total wake time and behavioral home cage activity (one-way ANOVA; p <0.001), while increasing REM and non-REM sleep times.
|
| [IC 50]
OX2; OX1 | [storage]
Store at +4°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|